Covid-19 roundup: Re­searchers call out Gilead for di­ver­si­ty of remde­sivir tri­als in NE­JM; Mex­i­co in vac­cine dose, tri­al talks

Racial and eth­nic mi­nor­i­ty groups suf­fer high­er rates of Covid-19 in­fec­tion, hos­pi­tal­iza­tion and death than white or non-His­pan­ic Amer­i­cans.

Yet when remde­sivir was test­ed in an NI­AID-fund­ed Adap­tive Covid-19 Treat­ment Tri­al, Black pa­tients ac­count­ed for 20% of par­tic­i­pants. And they ac­count­ed for just 11% of those as­signed to take the drug in a Gilead-fund­ed study, ac­cord­ing to the New Eng­land Jour­nal of Med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER